PL
EDIT icon

Plancorp LLC’s Editas Medicine EDIT Stock Holding History

Plancorp LLC’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,765
Closed -$264K – 209
2020
Q4 		$264K Buy
+3,765
New +$155K 0.07% 172
2018
Q1 		– Sell
-7,649
Closed -$235K – 163
2017
Q4 		$235K Buy
+7,649
New +$193K 0.08% 153

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Plancorp LLC's EDIT Position: Q1 2021 in Review

Plancorp LLC sold out of Editas Medicine (EDIT) in Q1 2021, closing a stake of 3,765 shares — an estimated $264K sold.

Plancorp LLC first reported a position in EDIT in Q4 2017 and held it in 2 quarters. The position peaked at $264K in Q4 2020. 312 funds tracked by Wall St. Rank hold EDIT as of Q1 2021.

  • Plancorp LLC reported no remaining Editas Medicine position as of Q1 2021 after selling out during the quarter.
  • Plancorp LLC sold 3,765 Editas Medicine shares in Q1 2021, an estimated $264K.
  • Plancorp LLC first reported a position in Editas Medicine in Q4 2017 and held it in 2 quarters.
  • Plancorp LLC's Editas Medicine position peaked at $264K in Q4 2020.
  • 312 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2021.

Based on Plancorp LLC's 13F filing for Q1 2021, filed 14 May 2021.